Unproven Drugs Allowed to Remain on Market By FDA

Angel Reyes
Attorney
(866) 735-1102 Ext 495
Visit Angel Reyes on FacebookVisit Angel Reyes on LinkedInVisit Angel Reyes on TwitterVisit Angel Reyes on Avvo
Posted by Angel ReyesNovember 02, 2009 1:28 PM

We trust organizations like the FDA to keep us safe. After all, that's why they were created in the first place, right?

Well, a new report by the Government Accountability Office (GAO) suggests that the FDA has failed to pull several drugs that are currently on the market, despite studies that indicate that these drugs lack any real health benefits.

The problem started in 1992, when the FDA began a new method for approving drugs by using "surrogate endpoints". Basically, the FDA would use the results of initial tests on a drug to try and predict the long-term effects that the drug will have. This policy was implemented to shorten the time it takes to get critically-needed medications on the market, as well as to lower the costs of medication production by eliminating expensive repeated trials.

One example of this is the use of HIV-drugs, which were approved based on initial tests showing their virus-lowering capabilities.

According to the Associated Press:

The FDA approved AstraZeneca's lung cancer drug Iressa in 2003 based on early results showing it reduced the size of tumors. But later studies showed the drug did not significantly extend patient lives.

The FDA has left the drug on the market, despite hundreds of reports of a sometimes fatal pneumonia.

FDA officials explain that access to Iressa has been restricted to a small number of patients who have shown benefit. The agency recommends all other patients try two alternative drugs.

Many of the drugs that were tested with "surrogate endpoints" did end up being as successful as their initial tests predicted. Nevertheless, since 1992, the FDA has failed to pull even one drug off the market due to missing or inconclusive data, despite the fact that outside studies have determiend that many of these drugs are not beneficial to patients.

This lack of follow-through is dangerous and costly to patients who are paying for medications that may not even help them. It is a shame that the FDA, which we rely on to keep us safe in so many ways, is the organization behind this scandal.

0 Comments

Have an opinion about this post? Please consider leaving a comment or subscribing to the feed to have future articles delivered to your feed reader.

Leave a comment

Have an opinion? There are 3 ways to leave a public comment (or click here to email the author privately).

For information on acceptable commenting practices, please visit Lifehacker's guide to weblog comments. Comments containing spam or profanity will be filtered or deleted.

Method 1: Guests

Provide the information below. Your email address will not be published or sold.

Name:

Email Address:

URL:

Method 2: Facebook Users

Connect using your facebook account.

Method 3: InjuryBoard Members and Contributors

Please sign in

Comments:

5000 characters remaining.




Subscribe to InjuryBoard North Dallas

InjuryBoard North Dallas RSS Feeds

Keep up with the latest updates using your favorite RSS reader

Injury Board North Dallas is brought to you by Reyes Bartolomei Browne

Legal Assistance Center

More Info
Reyes Bartolomei Browne (866) 735-1102 Ext 495 www.reyeslaw.com
google
Personal Injury Lawyers Serving: North Dallas, Allen, Carrolton, Denton, Farmers Branch, Flower Mound, Frisco, Garland, Irving, Lewisville, Mckinney, Plano, Richardson, Rockwall, Rowlett, Addison
5950 Berkshire LaneSuite 410, Dallas, Texas 75225 [ Show Map ]
Better Business Bureau Accredited Business Confidential

Your question will be referred to an attorney near you. If your question is of a legal nature, then by submitting this form you agree you are not forming a formal attorney / client relationship. Read our full privacy policy.

Looking for an InjuryBoard attorney closer to home? Click here.

Subscribe to Blog Updates

Enter your email address if you would like to receive email notifications when comments are made on this post.

Email address